Content
At BD, we believe that people are at the heart of every breakthrough, solution, and step forward. Our Purpose drives us to create innovative solutions that make a meaningful impact on advancing the world of health™. We know that possibilities are endless when people feel supported and inspired. From our robust benefits to our inclusive, growth-focused culture, we’re here to help you thrive both professionally and personally.
Enabling you to advance patient care at each step
In addition, excluded from adjusted EBIDTA margin are certain costs that BD does not allocate to its organizational units, such as, among other things, foreign exchange, certain general and administrative expenses, and share based compensation expense. BD does not attempt to provide reconciliations of forward-looking adjusted EBITDA margin to the comparable GAAP measure because the impact and timing of these potential charges or gains are inherently uncertain and difficult to predict and are unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a material impact on GAAP measures of the Biosciences and Diagnostic Solutions business’s financial performance.
Latest Financial Results
These include revenue for New BD adjusted for a full year of Advanced Patient Monitoring revenue generated during Edwards Lifesciences’ ownership and adjusted EBITDA margin on a forward-looking basis for the Biosciences and Diagnostic Solutions business. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States. BD strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by BD may differ from similar measures used by other companies, even when similar terms are used to identify such measures. Non-GAAP measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Reconciliation of New BD revenue to the comparable GAAP measure is included in the accompanying presentation available on BD’s website, /investors.
Diagnostic Solutions is a leader in microbiology and infectious disease diagnostics, including molecular diagnostics, cervical cancer screening, microbiology automation and point-of-care offerings. Both businesses have strong leadership teams with unparalleled commercial, engineering and R&D expertise, and are dedicated to bringing the next generation of high-quality innovations to researchers, clinicians and patients. BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. BD is a global medical technology company that is advancing the world of healthTM by improving medical discovery, diagnostics and the delivery of care. BD is the one of the largest medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. Non-GAAP Financial MeasuresThis news release contains certain non-GAAP financial measures.
BD and more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.
Together We Advance
The Biosciences and Diagnostic Solutions business is also expected to benefit from enhanced focus and investments as a pure-play Life Sciences Tools and Diagnostics leader. The business is expected to have approximately $3.4 billion in fiscal 2024 revenue with a $22+ billion addressable market growing at mid- to high-single-digits, with more than 80% recurring revenue, and approximately 30% adjusted EBITDA margins. Biosciences is a leader in immunology and cancer research solutions and related clinical diagnostics, including flow cytometry instruments and reagents, and has innovative single-cell multiomics tools.
It enables labs to maximize performance using enhanced microbiology diagnostic informatics through a single, advanced platform with an intuitive, personalized user interface. The system helps collect clinical specimens containing aerobic, anaerobic and fastidious bacteria from the collection site, and transport them to the testing laboratory. In the lab, BD ESwab® specimens are processed using standard clinical lab operating procedures https://betinwin-bd.com/bd/ for bacterial culture. The unique design of the flocked swab ensures optimal elution of the specimen into the transport medium.
Our Corporate Sustainability strategy—a four-pillar framework called Together We Advance—embraces the connections and interdependence between company health, planet health, community health and human health. Through this framework, we address the most relevant Corporate Sustainability issues for our business and stakeholders. Based in Mexico City, to produce syringes, needles and clinical thermometers for the Mexican market. 1991 BD opens a central distribution center in Temsee, Belgium to ship medical products across Europe, the middle east, and Africa. 1995 A joint venture was established in China to produce medical products for China.